CEVA trial confirms efficacy of Tiludronate for the treatment of bone spavin
CEVA Animal Health has published a trial which, according to the company, shows that horses suffering lameness caused by bone spavin can show marked improvement following treatment with a Tiludronate infusion, in combination with controlled exercise. Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints which, says CEVA, is considered to be one of the most common forms of hindlimb lameness in the horse. The double-blind, multicentric, placebo-controlled trials were carried out on a total of 108 pleasure horses, show jumpers and eventers of a variety of sizes and breeds, all...